Stock Events

Stock Events

Fate Therapeutics 

$2.48
97
+$0.06+2.27% 17:20 Today

Statistics

Day High
2.48
Day Low
2.38
52W High
3.23
52W Low
0.93
Volume
224,931
Avg. Volume
2,898,350
Mkt Cap
296.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.38
-0.34
-0.29
-0.25
Expected EPS
-0.271
Actual EPS
N/A

Financials

-2,051.08%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
6.65MRevenue
-136.32MNet Income

Analyst Ratings

5.83Average Price Target
The highest estimate is 7.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FATE. It's not an investment recommendation.
AMD
23
AMD
Amazon
20
AMZN
NVIDIA
20
NVDA
Tesla
19
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the cell therapy space targeting similar diseases.
Novartis
NVS
Mkt Cap292.35B
Novartis offers CAR-T cell therapies, directly competing in the oncology segment with cell-based therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T therapy space, similar to Fate's focus.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, directly competing with Fate's off-the-shelf cell therapy approach.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops gene therapies for genetic diseases, indirectly competing in the cell and gene therapy sector.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has investments in gene therapy and CAR-T cell therapy, making it a competitor in the cell therapy market.
First Trust Indxx NextG
NXTG
Mkt Cap0
NextCure focuses on novel immunomedicines, competing in the immune-oncology market with a focus on novel cell therapies.

About

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Show more...
CEO
Bahram Valamehr
Employees
161
Country
United States
ISIN
US31189P1021
WKN
000A1W50M

Listings

STU
DE
F6T.STU
BOATS
BOATS
FATE.BOATS
MU
DE
F6T.MU
XNAS
US
FATE

0 Comments

Share your thoughts

FAQ

What is Fate Therapeutics stock price today?▼
The current price of FATE is $2.48 USD — it has increased by +2.27% in the past 24 hours. Watch Fate Therapeutics stock price performance more closely on the chart.
What is Fate Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Fate Therapeutics stocks are traded under the ticker FATE.
Is Fate Therapeutics stock price growing?▼
FATE stock has risen by +1.65% compared to the previous week, the month change is a -3.89% fall, over the last year Fate Therapeutics has showed a +153.88% increase.
What is Fate Therapeutics market cap?▼
Today Fate Therapeutics has the market capitalization of 296.56M
When is the next Fate Therapeutics earnings date?▼
Fate Therapeutics is going to release the next earnings report on October 29, 2026.
What were Fate Therapeutics earnings last quarter?▼
FATE earnings for the last quarter are -0.25 USD per share, whereas the estimation was -0.25 USD resulting in a +1.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Fate Therapeutics revenue for the last year?▼
Fate Therapeutics revenue for the last year amounts to 6.65M USD.
What is Fate Therapeutics net income for the last year?▼
FATE net income for the last year is -136.32M USD.
How many employees does Fate Therapeutics have?▼
As of September 04, 2026, the company has 161 employees.
In which sector is Fate Therapeutics located?▼
Fate Therapeutics operates in the Health & Wellness sector.
When did Fate Therapeutics complete a stock split?▼
Fate Therapeutics has not had any recent stock splits.
Where is Fate Therapeutics headquartered?▼
Fate Therapeutics is headquartered in SAN DIEGO, United States.